Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Merck (NYSE:MRK) received European Union approval for KEYTRUDA in combination regimens for adults with platinum-resistant ...

Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J. - Merck is spending $6.7 billion to bolster its cancer drug portfolio. That's ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...